Horizon Pharma, Inc.

+$0.72 (+0.7%)
Closing price March 24, 2023
Horizon Pharma shares exploded on Thursday after the firm announced results from its late-stage trial evaluating teprotumumab for the treatment of active thyroid eye disease.
The top analyst upgrades, downgrades and other research calls from Wednesday included Altice, Blue Apron, CubeSmart, Horizon Pharma, KB Home, Las Vegas Sands, Mylan and Switch.
The top analyst upgrades, downgrades and other research calls from Monday include Applied Materials, Barrick Gold, Comcast, GoDaddy, Intel, PG&E, Qualcomm and Sirius XM.
Here are 10 top Ireland-based public companies with shares that are traded in the United States that may be worth putting on a watchlist.
These five top companies with different health care businesses all can provide nice exposure to the sector in growth portfolios. All are rated Buy at Jefferies and make sense now.
24/7 Wall St. screened the Stifel specialty pharmaceutical list and found five stock rated Buy that have massive upside potential and probably don’t have the investment risk of some of the more...
The top analyst upgrades, downgrades and other research calls include Archer Daniels Midland, BlackRock, DexCom, Mallinckrodt, McDonald's, Philip Morris and Redfin.
Horizon Pharma released a better than expected quarterly earnings report before the markets opened on Monday.
The analysts at Stifel have focused on biotech and specialty pharma companies that not only have data that could prove to be huge, but they are offering aggressive accounts the best entry points in...
Pandora, Hertz, Horizon Pharma, and Chicago Bridge & Iron all posted new 52-week lows on Tuesday.
Horizon Pharma, TherapeuticsMD, DDR Corp., and Cobalt Energy all posted new 52-week lows on Monday.
Horizon Pharma PLC (NASDAQ: HZNP) saw its shares hit a 52-week low on Monday after the company released its first-quarter financial results. The company said that it had $0.21 in EPS and $220.9...
The S&P 500 and Dow are pushing new highs as 2016 comes to a close. While the post-election tailwind has been incredibly strong, there are still companies holding back this rally.
Horizon Pharma PLC saw its shares take a big step back on Thursday after the company reported topline results from one of its late-stage trials.
Horizon Pharma PLC (NASDAQ: HZNP) reported its third-quarter financial results on Monday before the markets opened. The company said that it had $0.70 in earnings per share (EPS) and $208.7 million...